Long-Awaited Major Test of Possible Lyme Vaccine is Now Underway

Long-Awaited Major Test of Possible Lyme Vaccine is Now Underway

Pfizer along with a French partner have announced the largest clinical trial for an experimental vaccine that could be the only way to stop Lyme disease, the two companies announced on Monday.

Although most people can get rid of the disease through a course of antibiotics, some suffer for years with persistent symptoms.

If not treated properly, Lyme can cause arthritis or heart problems and can affect your nervous system. A prior Lyme treatment, LYMErix, was taken off the market in 2002 following concerns over its safety

which were never proven and slowed public interest. The manufacturer, GlaxoSmithKline, withdrew it. The study, in partnership with French company Valneva

VLA15 is given in three doses that are and then an additional booster. Half of the participants will be given placebo saline for the first three doses, and half will receive the saline-based placebo as an extra dose The company stated.

The vaccine is a targeted attack on an outer layer protein in Borrelia burgdorferi bacteria, which causes Lyme disease. Blocking this protein may hinder the ability of the bacteria to leap from person to tick.

The vaccine is protected against six types of protein that are produced by bacteria that live within North America as well as Europe.

In the earlier tests, both in individuals and in labs and in labs, this vaccine “demonstrated a strong immune response and satisfactory safety profile,” the companies stated.

Long-Awaited Major Test

Long-Awaited Major Test